Latest Market Growth News

HUB24 Limited has reported a standout FY25 with robust revenue growth, record net inflows, and a significant dividend increase, reinforcing its leadership in Australia's wealth management platform sector.

Carnegie Clean Energy launches a $3 million Share Purchase Plan to fuel commercialisation of its wave and MoorPower technologies, capitalising on growing global momentum in ocean energy.

Novatti’s majority-owned subsidiary AUDC has closed a $1.2 million Seed Round, valuing Novatti’s 57% stake at $7 million as stablecoin adoption accelerates globally and locally.

Activeport Group has unveiled Private-Cloud Connect, Australia’s first variable bandwidth fibre network for private cloud services, securing three major data centre customers shortly after launch.

Temple & Webster has reported a robust 21% revenue increase in FY25, alongside a near sixfold jump in net profit, setting a confident tone for FY26 with strong early trading and an optimistic outlook.

AGL Energy reported a statutory loss for FY25 but maintained solid underlying profits, while setting ambitious growth and sustainability targets for FY26. The company’s evolving strategy highlights investments in battery storage and renewable capacity as it adapts to market challenges.

Oneview Healthcare reported a robust 36% revenue increase in H1 2025, driven by US market growth and the launch of its AI-powered Care Assistant, Ovie. Operational restructuring and AI innovation underpin its strategy for scalable, efficient deployments.

The Calmer Co. has secured a long-term lease for its Navua facility in Fiji, replacing a planned property purchase and freeing up capital to accelerate its US market expansion.

Memphasys Limited pivots from development to commercial execution with its flagship IVF product Felix, targeting global markets through direct sales and recurring revenue streams.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

ReNerve Limited reported a robust 53% increase in annual revenue, driven by strategic partnerships and new regulatory approvals that broaden its global footprint in nerve repair.